Skip to main content

Table 2 Adverse events reported at the 1-year follow-up examination

From: Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial

 

Abatacept (n = 43)

Rituximab (n = 46)

TNFi (n = 50)

Total (n = 139)

 

Number of events

Number of patients

Number of events

Number of patients

Number of events

Number of patients

Number of events

Number of patients

Cardiovascular event

1

1

2

2

2

2

5

5

Infection

9

6

5

4

11

7

25

18

Malignancy

0

0

3

3

0

0

3

3

Laboratory abnormalitiesa

1

1

0

0

2

2

3

3

Skin condition

3

3

3

3

6

5

12

11

Gastroenterological

2

2

3

3

0

0

5

5

Otherb

5

4

7

5

7

4

19

13

Total

21

16

23

15

28

20

78

51

  1. aLiver function test elevations and leukopenia. bIn this group, the adverse effects consisted primarily of influenza, fever, fatigue, headache and/or dizziness. One patient in the abatacept group developed psychosis 4 months after the start of the study.